25.05.2017 • NewsElaine Burridgemubadalainvestment

Kazakhstan and UAE Link on PE Project

(c) David BurtonFuse/Getty Images
(c) David BurtonFuse/Getty Images

A Memorandum of Understanding (MoU) for a joint-venture PE plant has been signed between Kazakhstan’s Unified Chemical Company and Abu Dhabi’s Mubadala Investment Company. The MoU will look at the technical and economic feasibility of building a complex in the Atyrau special economic zone in Kazakhstan.

The agreement follows an official visit by Kazakhstan’s President, Nursultan Nazarbayev, to the United Arab Emirates last January when negotiations about a petrochemicals’ cooperation were started.

Kazakhstan’s government is trying to develop its petrochemical industry to meet domestic demand. It estimates that imports account for more than 70% of domestic petrochemicals consumption currently. The country is aiming to primarily build new plants to produce polymers, such as PP and PE. Last October, Kazakhstani newspaper Astana Times reported that Kazakhstan Petrochemical Industries and China Development Bank had signed a $2 billion loan agreement for a gas chemical complex that would produce 500,000 t/y PP.

Mubadala Investment Company was created by the merger of Mubadala Development Company and International Petroleum Investment Company (IPIC) earlier this year in a bid to cut costs. Its assets include stakes in Spanish energy group Cepsa, Austrian polyolefins group Borealis and Canada’s Nova Chemicals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.